Briefly Bio, based in London, has secured $1.2M in pre-seed funding to tackle the reproducibility crisis plaguing the scientific community.
By leveraging AI technology, this biotech startup is poised to transform how lab experiments are documented, ensuring accuracy and consistency.
Addressing Science’s Reproducibility Crisis
The international scientific community is grappling with a profound reproducibility crisis, affecting over half of preclinical research efforts. This issue results in staggering annual losses exceeding $50 billion. Through AI-powered solutions, Briefly Bio is determined to rectify this by facilitating the consistent and clear documentation of lab experiments, ultimately fostering better scientific collaboration.
Cutting-Edge Software Innovation
Modern-day biological experiments, marked by increasing complexity, often suffer from incomplete documentation. This inadequacy hampers fruitful scientific collaboration. To address this, Briefly Bio has developed innovative AI-powered software that acts as a shared language for experiment documentation. This tool standardises experiments by converting their descriptions into a uniform format, automatically identifying errors and filling in missing gaps to enhance collaboration and allow smoother operations for data scientists and automation teams.
Diverse Expertise of Founders
The team behind Briefly Bio includes Dr Katya Putintseva, Harry Rickerby, and Staffan Piledahl. Their collective expertise spans academia, technology, biotechnology, and robotics. Before founding Briefly Bio, the trio was instrumental at LabGenius, a drug discovery startup, where they advanced a machine learning-driven antibody discovery platform. According to Rickerby, codifying scientific methods is as crucial as software code; they are intrinsic instructions necessitating consistency, similar to GitHub’s influence in software engineering.
Implications for the Scientific Community
Addressing the reproducibility challenge is critical for the scientific domain. Briefly Bio’s software is poised to revolutionise research methodologies, promising greater accuracy and efficiency in scientific discoveries. The newly procured $1.2M funding aims to augment the platform’s development further, thereby expanding its functional capabilities.
Industry-Endorsed Recognition
The debut of Briefly Bio has been met with enthusiastic acclaim from industry veterans. Dr Gena Nikitin heralded the software as a breakthrough in experimental documentation. Similarly, Dr Maria Anastasina underscored its significance in lab management. PhD candidate Suparna Kumar finds it indispensable, while Rob Harkness lauds its ability to streamline and automate lab workflows. Shelby Newsad, an investor, appreciates the protocol-focused approach, emphasizing its potential in improving reproducibility by standardising methods.
Founders’ Background and Mission
Founded by Dr Katya Putintseva, Harry Rickerby, and Staffan Piledahl, who collaborated at LabGenius, Briefly Bio was born from firsthand challenges experienced by each founder in their respective fields. Putintseva’s quest for precise data generation, Piledahl’s focus on complete workflow definitions and Rickerby’s efforts in enhancing lab workflows informed their mission to resolve inconsistencies in lab documentation.
Overcoming Traditional Documentation Challenges
Historically, scientists document their experiments using personalised narratives, which often lead to ambiguities. To counteract this, Briefly Bio offers a structured format that refines descriptions, automatically completing and improving them. This allows for effective tracking of scientific methods as they evolve, presenting a significant leap from previous textual formats.
Target Audience and Applications
The typical users of Briefly Bio’s platform include wet lab scientists engaged in early-stage R&D, from both academic and industrial backgrounds. It also facilitates better cohesion between scientists and those involved in laboratory automation, by streamlining documentation processes. The platform is instrumental in reducing time spent on documentation, thus enhancing collaboration and accelerating automation of workflows.
Vision for Future Developments
With future plans to open its platform to the public, Briefly Bio envisions an environment where experiments and protocols might be easily shared among researchers, akin to GitHub’s role in open-source software. This availability aims to expedite the discovery of reproducible methodologies, paving the way for future scientific breakthroughs.
Briefly Bio stands at the forefront of addressing a major issue in science.
With its AI-driven solution, the startup is set to significantly enhance research reliability and collaboration.
The recent funding marks a pivotal point in its mission to reshape scientific documentation.
